Abel Humberto Villanueva-Compean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abel Humberto Villanueva-Compean has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Esquivel Pineda
Centro Médico ABC
1 shared publication Alonso Cruz-Cruz
IMSS
1 shared publication- Arturo Cérbulo-Vázquez
Laboratorio de Proteómica y Metabolómica, Dirección de Investigación, Hospital General de México “Dr. Eduardo Liceaga”, Ciudad de México 06720, Mexico
1 shared publication Berenice Zavala-Barrios
1 shared publication- Constantino López-Macías
Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico
1 shared publication - David Serrano-Molina
IMSS
1 shared publication
Latest Publications
- Open Access
Serological Cytokine and chemokine profile in pregnant women with COVID19 in Mexico City
On January 30th, 2020, the WHO declared the outbreak of COVID19, a disease due to the new coronavirus called SARS-CoV-2. Certain comorbidities, symptoms and signs are characteristic of COVID19 in the general population and in pregnant women. However, pregnant women are considered as a high-risk group for COVID19. To know about the frequency of comorbidities, signs and symptoms, the presence of lymphopenia, antibodies response to SARS-CoV2 and cytokine and chemokine serum concentration, six pregnant women with COVID19 were studied at the moment of admission. The lower concentration of CCL17 was detected in the Pregnant COVID19 group, similar concentration of IL-6 was also detected in non-pregnant and pregnant COVID19 patients. Our result show that pregnant and non-pregnant women with COVID19 has similar cytokine profile.
Open AccessSerological Cytokine and chemokine profile in pregnant women with COVID19 in Mexico City
On January 30th, 2020, the WHO declared the outbreak of COVID19, a disease due to the new coronavirus called SARS-CoV-2. Certain comorbidities, symptoms and signs are characteristic of COVID19 in the general population and in pregnant women. However, pregnant women are considered as a high-risk group for COVID19. To know about the frequency of comorbidities, signs and symptoms, the presence of lymphopenia, antibodies response to SARS-CoV2 and cytokine and chemokine serum concentration, six pregnant women with COVID19 were studied at the moment of admission. The lower concentration of CCL17 was detected in the Pregnant COVID19 group, similar concentration of IL-6 was also detected in non-pregnant and pregnant COVID19 patients. Our result show that pregnant and non-pregnant women with COVID19 has similar cytokine profile.